Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression

AIDS

Volumn 28, Issue 9, 2014, Pages 1261-1272

  Dalmau, Judith ^a   Rotger, Margalida ^b   Erkizia, Itziar ^a   Rauch, Andri ^c   Reche, Pedro ^d   Pino, Maria ^a   Esteve, Anna ^f   Palou, Eduard ^g   Brander, Christian ^a,i   Paredes, Roger ^a   Phung, Pham ^e   Clotet, Bonaventura ^a,h   Telenti, Amalio ^b   Martinez Picado, Javier ^a,h,i   Prado, Julia G ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e MONOGRAM BIOSCIENCES   (United States)

^f Centre d'Estudis Epidemiologics sobre les Infeccions de Transmissio Sexual i SIDA de Catalunya   (Spain)

^g BANC DE SANG I TEIXITS   (Spain)

^h UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

ⁱ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

HIV 1; Host factors; Pathogenesis; Rapid progressors; Viral factors

Indexed keywords

DRUG ANALYSIS; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RECEPTOR;

ADAPTATION; ADAPTIVE IMMUNITY; ADULT; ALLELE; ARTICLE; BLOOD; CD8+ T LYMPHOCYTE; CLASSIFICATION; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENETICS; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; NONHUMAN; PATHOGENESIS; PHYSIOLOGY; PRIORITY JOURNAL; VIROLOGY; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ADAPTATION, BIOLOGICAL; ADULT; ANALYSIS; BLOOD; CD8-POSITIVE T-LYMPHOCYTES; CLASSIFICATION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC VARIATION; GENETICS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGY; MALE; PHYSIOLOGY; RECEPTORS, HIV; VIROLOGY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84927654018     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000293     Document Type: Article

References (43)

1. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action Concerted Action on Sero- Conversion to AIDS and Death in Europe. Lancet 2000; 355:1131-1137.
2. Dalmau J, Puertas MC, Azuara M, Mariño A, Frahm N, Mothe B, et al. Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis 2009; 48:229-238.
3. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571.
4. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011; 121: 2391-2400.
5. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
6. Casado C, Colombo S, Rauch A, Martínez R, Günthard HF, Garcia S, et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One 2010; 5:e11079.
7. Dalmau J, Codoñer FM, Erkizia I, Pino M, Pou C, Paredes R, et al. In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection. PLoS One 2012; 7:e32714.
8. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-1038.
9. Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor- Williams G, Ndung'u T, et al. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J Virol 2010; 84:492-502.
10. Prado JG, Honeyborne I, Brierley I, Puertas MC, Martinez- Picado J, Goulder PJR. Functional consequences of human immunodeficiency virus escape from an HLA-BM13-restricted CD8R T-cell epitope in p1 Gag protein. J Virol 2009; 83:1018-1025.
11. Björndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-7487.
12. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092.
13. Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, Wrin T. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007; 46: 1-11.
14. Frost SDW, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005; 102:18514-18519.
15. Ferbas J, Daar ES, Grovit-Ferbas K, Lech WJ, Detels R, Giorgi JV, Kaplan AH. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J Virol 1996; 70:7285-7289.
16. Mohri H, Markowitz M. In vitro characterization of multidrugresistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr 2008; 48:511-521.
17. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, Souyris C, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24:2305-2312.
18. Richman DD, Bozzette SA. The impact of the syncytiuminducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-974.
19. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, et al. Higher CD4R T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004; 190:251-256.
20. Daar ES, Kesler KL, Wrin T, Petropoulo CJ, Bates M, Lail A, et al. HIV-1 pol replication capacity predicts disease progression. AIDS 2005; 19:871-877.
21. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-645.
22. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, et al. Evolution of HLA-BM5703 HIV-1 escape mutations in HLA-BM5703-positive individuals and their transmission recipients. J Exp Med 2009; 206:909-921.
23. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-338.
24. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-3623.
25. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007; 81:12382-12393.
26. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 2004; 78:8927-8930.
27. Schneidewind A, Brumme ZL, Brumme CJ, Power KA, Reyor LL, O'Sullivan K, et al. Transmission and long-term stability of compensated CD8 escape mutations. J Virol 2009; 83:3993-3997.
28. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 2012; 205:174-184.
29. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4R cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
30. Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1- specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol 1999; 73:5509-5519.
31. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
32. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(R) T lymphocyte mobilization to virus-infected tissue requires CD4(R) T-cell help. Nature 2009; 462:510-513.
33. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012; 122:3271-3280.
34. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012; 122:3281-3294.
35. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928-935.
36. Peterson TA, Kimani J, Wachihi C, Bielawny T, Mendoza L, Thavaneswaran S, et al. HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort. Tissue Antigens 2013; 81:93-107.
37. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8R T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.
38. Saéz-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007; 104:6776-6781.
39. Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24- specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006; 80:3122-3125.
40. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375-386.
41. Hollingsworth T, Anderson R, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
42. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviralnaive individuals. J Infect Dis 2005; 192:466-474.
43. Herbeck JT, Müller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, et al. Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS 2012; 26:193-205.